Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

VIR

V

Vir Biotechnology, Inc. (VIR)

NMS – Real Time Price. Currency in USD

8.40

-0.56 (-6.25%)

At close: Mar 27, 2026, 4:00 PM EDT

8.50

+0.10 (1.19%)

After-hours: Mar 27, 2026, 7:53 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology to Participate in Upcoming Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston, Massachusetts. Leerink Partners Global Healthcare Conference: Marianne De Backer, M.

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, bef.

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology Announces Proposed Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000.

Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and multiple oncology indications.

These Analysts Boost Their Forecasts On Vir Biotechnology

These Analysts Boost Their Forecasts On Vir Biotechnology

Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.

What's Happening With VIR Stock?

What's Happening With VIR Stock?

Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging Phase 1 results. This information, combined with an impressive revenue exceedance, is fostering considerable optimistic sentiment.

Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, bef.

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology Announces Proposed Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. “This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr.

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising an.